Andrew Booth

Chief Financial Officer

Andrew Booth (Chief Financial Officer) filed 2 Form 4 reports in the trailing twelve months (2 purchases, 0 sales), most often in AbCellera Biologics Inc. (ABCL). Across 2 priced purchase filings, the average 21-session return was -0.9% from execution and -0.9% from disclosure (delay-adjusted; derived). The largest single filing was $384K of ABCL (37,200 sh × $10.32, as filed), executed Aug 14.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

-0.9%

avg across 2 priced filings

Delay-adjustediThe same average, entered at disclosure dates

-0.9%

same 2 filings, from disclosure

Filings, ttm

2 buys · 0 sells

Median delay

execution → disclosure

Volume, ttmiDollar value disclosed in the trailing twelve months

$530K

shares × price, as filed

Last traded

Aug 14

Filed Aug 14

Median ADV $89.1M across their filed names

Open performance→

Volume by month

Buys $530K Sells $0

Shares × price, as filed · by filing month · past 24 months

Sectors filed on

Healthcare 2 filings

Sector per market data · by filing · past 12 months

Most traded names

ABCL

AbCellera Biologics Inc. ABCL · 2 buys · 0 sells 2 filings

Recent filings

ABCLPURCHASE AbCellera Biologics Inc. View filing → $384K
37,200 sh × $10.32
Exec Aug 14
Filed Aug 14 · 12:04 PM ET ABCLPURCHASE AbCellera Biologics Inc. View filing → $146K
42,600 sh × $3.42
Exec Feb 27
Filed Feb 27 · 2:48 PM ET